Your browser doesn't support javascript.
loading
Covalent ERα Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast Cancer.
Furman, Craig; Puyang, Xiaoling; Zhang, Zhaojie; Wu, Zhenhua J; Banka, Deepti; Aithal, Kiran B; Albacker, Lee A; Hao, Ming-Hong; Irwin, Sean; Kim, Amy; Montesion, Meagan; Moriarty, Alyssa D; Murugesan, Karthikeyan; Nguyen, Tuong-Vi; Rimkunas, Victoria; Sahmoud, Tarek; Wick, Michael J; Yao, Shihua; Zhang, Xun; Zeng, Hao; Vaillancourt, Frédéric H; Bolduc, David M; Larsen, Nicholas; Zheng, Guo Zhu; Prajapati, Sudeep; Zhu, Ping; Korpal, Manav.
Affiliation
  • Furman C; H3 Biomedicine Inc., Cambridge, Massachusetts.
  • Puyang X; H3 Biomedicine Inc., Cambridge, Massachusetts.
  • Zhang Z; H3 Biomedicine Inc., Cambridge, Massachusetts.
  • Wu ZJ; H3 Biomedicine Inc., Cambridge, Massachusetts.
  • Banka D; H3 Biomedicine Inc., Cambridge, Massachusetts.
  • Aithal KB; Aurigene Discovery Technologies Ltd, Bangalore, Karnataka, India.
  • Albacker LA; Foundation Medicine Inc., Cambridge, Massachuetts.
  • Hao MH; H3 Biomedicine Inc., Cambridge, Massachusetts.
  • Irwin S; H3 Biomedicine Inc., Cambridge, Massachusetts.
  • Kim A; H3 Biomedicine Inc., Cambridge, Massachusetts.
  • Montesion M; Foundation Medicine Inc., Cambridge, Massachuetts.
  • Moriarty AD; START, Preclinical Research, San Antonio, Texas.
  • Murugesan K; Foundation Medicine Inc., Cambridge, Massachuetts.
  • Nguyen TV; H3 Biomedicine Inc., Cambridge, Massachusetts.
  • Rimkunas V; H3 Biomedicine Inc., Cambridge, Massachusetts.
  • Sahmoud T; H3 Biomedicine Inc., Cambridge, Massachusetts.
  • Wick MJ; START, Preclinical Research, San Antonio, Texas.
  • Yao S; H3 Biomedicine Inc., Cambridge, Massachusetts.
  • Zhang X; H3 Biomedicine Inc., Cambridge, Massachusetts.
  • Zeng H; H3 Biomedicine Inc., Cambridge, Massachusetts.
  • Vaillancourt FH; H3 Biomedicine Inc., Cambridge, Massachusetts.
  • Bolduc DM; H3 Biomedicine Inc., Cambridge, Massachusetts.
  • Larsen N; H3 Biomedicine Inc., Cambridge, Massachusetts.
  • Zheng GZ; H3 Biomedicine Inc., Cambridge, Massachusetts.
  • Prajapati S; H3 Biomedicine Inc., Cambridge, Massachusetts.
  • Zhu P; H3 Biomedicine Inc., Cambridge, Massachusetts.
  • Korpal M; H3 Biomedicine Inc., Cambridge, Massachusetts.
Mol Cancer Ther ; 21(6): 890-902, 2022 06 01.
Article in En | MEDLINE | ID: mdl-35642432
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms Limits: Female / Humans Language: En Journal: Mol Cancer Ther Year: 2022 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms Limits: Female / Humans Language: En Journal: Mol Cancer Ther Year: 2022 Document type: Article